Given that the volume loss and atrophy of retroslenial cortex (RS) was observed at the earliest clinical stage of AD (Pengas et al., 2010), we further examined GFAP and IBA1 immunoreactivity in the RS of cDKO mice at 6 weeks and 2 months of age. This evidence concerns the gene GFAP and Alzheimer disease.